心血管疾病的免疫治疗
CANTOS试验明确证实炎症是动脉粥样硬化的关键驱动因素,使用抗IL-1β抗体canakinumab靶向炎症可改善心血管疾病结局,尤其对具有促炎体质的患者。但canakinumab未改善心血管死亡,且增加感染风险,因此需识别新靶点并开发阻断动脉粥样硬化特异性炎症通路、免疫抑制副作用有限的疗法。本综述重点介绍当前被视为未来心血管疾病治疗方向的新型免疫治疗靶点。
要点
- CANTOS证实抗IL-1β抗体靶向炎症可改善CVD结局,尤其促炎体质患者。
- canakinumab未改善CVD死亡且增加感染,需开发免疫抑制副作用有限的新靶点。
- 本综述聚焦动脉粥样硬化特异性炎症通路的新型免疫治疗靶点。
核心结论
- CANTOS试验明确证实炎症是动脉粥样硬化的关键驱动因素,靶向炎症可改善CVD结局。
- canakinumab未改善CVD死亡且增加感染,需开发阻断动脉粥样硬化特异性炎症通路且免疫抑制副作用有限的新疗法。
研究设计与样本
- 本文为综述,围绕CANTOS试验结果及新型免疫治疗靶点进行论述。
主要发现
- CANTOS试验使用抗白介素-1β抗体canakinumab靶向炎症,改善了心血管疾病结局,尤其对具有促炎体质的CVD患者。
- canakinumab治疗未改善CVD死亡率,并导致感染增加。
临床怎么用
- CANTOS支持对具有促炎体质的CVD患者靶向炎症治疗,但需权衡感染风险。
- 未来应关注阻断动脉粥样硬化特异性炎症通路且免疫抑制副作用有限的新型免疫治疗靶点。
局限性
- canakinumab未改善CVD死亡且增加感染,提示现有抗炎治疗需优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
引用
- Lutgens E, Atzler D, Döring Y, et al. Immunotherapy for cardiovascular disease. Eur Heart J. 2019. PMID: 31121017. doi:10.1093/eurheartj/ehz283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。